Evidence map›Paper›PMID 38599112›Full record

ArticleGynecologic oncology2024

Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.

Katherine W Saylor, Elizabeth Q Fernandes, Michael Adams, Sarah Paraghamian, David I Shalowitz

Abstract read
In one paragraph

Article in Gynecologic oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Katherine W SaylorDepartment of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, United States of America. Electronic address: kwsaylor@pennmedicine.upenn.edu.
Elizabeth Q FernandesUniversity of North Carolina School of Medicine, Chapel Hill, NC, United States of America.
Michael AdamsDivision of Pediatric Genetics and Metabolism, University of North Carolina School of Medicine, Chapel Hill, PA, United States of America.
Sarah ParaghamianDepartment of Obstetrics and Gynecology, Tufts University School of Medicine, Boston, MA, United States of America.
David I ShalowitzWest Michigan Cancer Center, Kalamazoo, MI, United States of America; Collaborative on Equity in Rural Cancer Care, Kalamazoo, MI, United States of America.

Funding

The Penn Postdoctoral Training Program in the Ethical, Legal and Social Implications of Genetics and GenomicsT32HG009496 · NHGRI · UNIVERSITY OF PENNSYLVANIA · PI Steven Joffe · 2017 to 2026
$3.4M
NHGRI NIH HHS T32 HG009496
6 · The paper itself

Abstract

objectivesTo identify predictors of referral and completion of germline genetic testing among newly diagnosed ovarian cancer patients, with a focus on geographic social deprivation, oncologist-level practices, and time between diagnosis and completion of testing.

methodsClinical and sociodemographic data were abstracted from medical records of patients newly diagnosed with ovarian cancer between 2014 and 2019 in the University of North Carolina Health System. Factors associated with referral for genetic counseling, completion of germline testing, and time between diagnosis and test results were identified using multivariable regression.

results307/459 (67%) patients were referred for genetic counseling and 285/459 (62%) completed testing. The predicted probability of test completion was 0.83 (95% CI: 0.77-0.88) for patients with a referral compared to 0.27 (95% CI: 0.18-0.35) for patients without a referral. The predicted probability of referral was 0.75 (95% CI: 0.69-0.82) for patients at the 25th percentile of ZIP code-level Social Deprivation Index (SDI) and 0.67 (0.60-0.74) for patients at the 75th percentile of SDI. Referral varied by oncologist, with predicted probabilities ranging from 0.47 (95% CI: 0.32-0.62) to 0.93 (95% CI: 0.85-1.00) across oncologists. The median time between diagnosis and test results was 137 days (IQR: 55-248 days). This interval decreased by a predicted 24.46 days per year (95% CI: 37.75-11.16).

conclusionsWe report relatively high germline testing and a promising trend in time from diagnosis to results, with variation by oncologist and patient factors. Automated referral, remote genetic counseling and sample collection, reduced out-of-pocket costs, and educational interventions should be explored.

Indexed as

Genetic CounselingGenetic TestingGerm-Line MutationOvarian NeoplasmsReferral and ConsultationAdultAgedCancer Care FacilitiesFemaleHumansMiddle AgedNorth CarolinaRetrospective StudiesAccess barriersGermline testingProvider variationReferral

Identifiers

PMID38599112
PMCPMC11216855

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.